The tools of the trade: Weapons of mass destruction

Emergency Medicine

Volumn 14, Issue 3, 2002, Pages 240-248

  Caldicott, David G E ^a   Edwards, Nicholas A ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Biological warfare agent; Bioterrorism; Chemical warfare agent; Nuclear; Radiological agent; Terrorism; Weapons of mass destruction

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIDOTE; CHEMICAL WARFARE AGENT; CHLORINE; CHLORMETHINE; CYANIDE; EXPLOSIVE; LEWISITE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; MUSCARINIC RECEPTOR; MUSTARD GAS; NICOTINIC RECEPTOR; ORGANOPHOSPHATE; PHOSGENE; PRALIDOXIME; SARIN; SMALLPOX VACCINE; SOMAN; TABUN; VACCINE;

ANTHRAX; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CHEMICAL WARFARE; CLINICAL TRIAL; HUMAN; INJURY; PRIORITY JOURNAL; REVIEW; SMALLPOX; TERRORISM; WEAPON;

BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CHEMICAL WARFARE AGENTS; EXPLOSIONS; HUMANS; MANUFACTURED MATERIALS; NUCLEAR WARFARE; VARIOLA VIRUS;

EID: 0036739517     PISSN: 10356851     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2026.2002.00338.x     Document Type: Review

References (76)

1. Wightman JM, Gladish SL. Explosions and blast injuries. Ann. Emerg. Med. 2001; 37: 664-78.
2. Stein M, Hirshberg A. Medical consequences of terrorism. The conventional weapon threat. Surg. Clin. North Am. 1999; 79: 1537-52.
3. Hodgetts TJ. Lessons from the Musgrove Park Hospital bombing. Injury 1993; 24: 219-21.
4. Leibovici D, Gofrit ON, Shapira SC. Eardrum perforation in explosion survivors: is it a marker of pulmonary blast injury? Ann. Emerg. Med. 1999; 34: 168-72.
5. Hogan DE, Waeckerle JF, Dire DJ, Lillibridge SR. Emergency department impact of the Oklahoma City terrorist bombing. Ann. Emerg. Med. 1999; 34: 160-7.
6. Derbes VJ. DeMussis and the Great Plague of 1348; a forgotten episode of bacteriological warfare. JAMA 1966; 196: 59-62.
7. Alibek K. Biohazard. London: Random House; 1999.
8. Henderson DA. The looming threat of bioterrorism. Science 1999; 283: 1279-82.
9. Spencer RC, Lightfoot NF. Preparedness and response to bioterrorism. J. Infect. 2001; 43: 104-10.
10. Kauffmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg. Infect. Dis. 1997; 3: 83-94.
11. Emergency Management. Australia Manual 3. Health Aspects of Chemical, Biological and Radiological Hazards. Australian Emergency Manuals Series (Part 3, Vol. 2). 2000.
12. Hawkes N. 'Dirty' bomb could wipe out thousands. The Times 26 October 2001.
13. Edwards R. The nightmare scenario. New Scientist 2001; 13: 10-12.
14. Allison G. Could worse be yet to come? The Economist 1 November 2001.
15. Weldon C. Chairman's Opening Statement. Research and Development Subcommittee Hearing on Nuclear Terrorism and Countermeasures. 1 October 1997. [Cited 10 Jul 2001.] Available from URL: http://www.fas.org/spp/starwars/congress/1997_h/h971001w.htm
16. Webster P, Watson R. Bin Laden's nuclear threat. The Times 26 October 2001: 1.
17. Cameron G. Nuclear terrorism reconsidered. Current History 2000; April: 154-7.
18. IAEA. Calculating the New Global Nuclear Terrorism Threat. (Press release). 31 October 2001. [Cited 1 Nov 2001.] Available from URL: http://www.iaea.or.at/worldatom/Press/P_release/2001/nt_summary.shtml
19. Jortani SA, Snyder JW, Valdes R Jr. The role of the clinical laboratory in managing chemical or biological terrorism. Clin. Chem. 2000; 46: 1883-93.
20. Gunderson CH, Lehmann CR, Sidell FR, Jabbari B. Nerve agents: a review. Neurology 1992; 42: 946-50.
21. Sidell FR, Takafuji ET, Franz DR (eds). Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, Office of the Surgeon General: TMM Publications, 2002. [Cited 3 Jan 2002.] Available from URL: http://www.chemdef.apgea.army.mil/textbook/contents.asp
22. Davis KG, Aspera G. Exposure to liquid sulphur mustard. Ann. Emerg. Med. 2001; 37: 653-6.
23. Smith WJ, Dunn MA. Medical defence against blistering chemical warfare agents. Arch. Dermatol. 1991; 127: 1207-13.
24. Szilagyi M, Dawson RM. Phosgene - a research review. Aust. Mil. Med. 1995; 4: 16-18.
25. Winder C. The toxicology of chlorine. Environ. Res. 2001; 85: 105-15.
26. Sauer SW, Keim ME. Hyroxocobalamin: improved public health readiness for cyanide disasters. Ann. Emerg. Med. 2001; 37: 635-41.
27. Eddleston M, Szinicz L, Eyer P, Buckley N. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. Q.J. Med. 2002; 95: 275-83.
28. Bajgar J. Some toxic chemicals as potential warfare agents-the threat for the future? ASA Newsletter 2000 [Cited 16 November 2001.] Available from URL: http://www.asanltr.com/newsletter/98-6/chemistry.html
29. Tour JM. Do-it-yourself chemical weapons. CENEAR 2001; 78: 42-5.
30. Harigel GG. The concept of weapons of mass destruction. Chemical and biological weapons-use in warfare, impact on society and environment. Proceedings of the Conference on Biosecurity and Bioterrorism. 18-19 September 2000, Instituto Diplomatico 'Mario Toscano', Rome, Italy.
31. ZARC. International Inc. Chemical Agents and Treaties. [Cited 16 November 2001.] Available from URL: http://www.zarc.com/english/chemical/nerve_agents.html
32. Anonymous. Russia's Covert Chemical Weapons Program Vindicates Jesse Helms' Continuing Opposition to Phony C.W. Arms Control. Discussion Brief. Publications of the Center for Security Policy, no. 97-D 19 4 February 1997.
33. Geddes A. Infection in the twenty-first century: predictions and postulates. J. Antimicrob. Chemother. 2000; 46: 873-7.
34. Block S. The growing threat of biological weapons. Am. Scientist 2001; 89: 2-11.
35. Ashraf H. US biological defense research under the spotlight. Lancet 2001; 358: 895.
36. NATO. NATO Handbook on the Medical Aspects of NBC Defensive Operations. Washington: Departments of the Army, Navy and Airforce. 1996.
37. CDC Strategic Planning Workgroup. Biological and chemical terrorism: strategic plan for preparedness and response. Morb. Mortal Wkly Report 2000; 49 (RR-4): 1-14.
38. Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 2127-37.
39. Henderson DA. Smallpox: Clinical and epidemiologic features. Emerg. Infect. Dis. 1999; 5: 534-6.
40. Inglesby TV, Henderson DA, Bartlett JG et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281: 1735-45.
41. Inglesby TV, O'Toole T, Henderson DA et al. Anthrax as a biological weapon: updated recommendations for management. JAMA 2002; 287: 2236-52.
42. Swartz MN. Recognition and management of anthrax-an update. NEJM 2001; 345: 1621-6.
43. Enserink M. This time it was real: knowledge of anthrax put to the test. Science 2001; 294: 490-1.
44. Mock M, Fouet A. Anthrax. Annu. Rev. Microbiol. 2001; 55: 647-71.
45. Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283: 2281-90.
46. Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2001; 285: 1059-70.
47. Dennis DT, Inglesby TV, Henderson DA et al. Tularaemia as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2001; 285: 2763-73.
48. Borio L, Inglesby TV, Peters CJ et al. Haemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391-405.
49. Vastag B. Surprise finding spurs ebola researchers' hopes. JAMA 2002; 287: 1381-2.
50. Burgess TH, Steele KE, Schoneboom BA, Grieder FB. Clinicopathological features of viral agents of potential use by bioterrorists. Clin. Lab. Med. 2001; 21: 475-93.
51. Shahin S. Melioidosis: Pathogenesis, epidemiology, treatment and detection. Aust. Mil. Med. 2001; 10: 21-7.
52. Pomerantsev AP, Staritsin NA, Mockov YuV, Marinin LI. Expression of cereolysin AB genes in Bacillus anthracis vaccine strain ensures protection against experimental haemolytic anthrax infection. Vaccine 1997; 15: 1846-50.
53. Centers for Disease Control. 2002. [Cited 3 Jan 2002.] Available from URL: www.cdc.gov
54. World Health Organisation. 2002. [Cited 3 Jan 2002.] Available from URL: www.who.International
55. Australian Department for Health and Ageing. 2002. [Cited 3 Jan 2002.] Available from URL: www.health.gov.au/pubhlth/strateg/communic/index,htm
56. Meselson M, Guillemin J, Hugh-Jones M et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-8.
57. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch. Intern. Med. 1998; 158: 429-34.
58. Alexeter Technologies LLC. 2002. [Cited 3 Jan 2002.] Available from URL: www.alexeter.com
59. McCarthy M. Early and aggressive treatment saves US anthrax victims. Lancet 2001; 358: 1703.
60. Blanck RR. Anthrax is based on medical evidence. Am. J. Public Health 2000; 90: 1326-7.
61. Butlin N. In: Our Original Aggression: Aboriginal Populations of South East Australia 1788-850. Sydney: Allen & Unwin, 1983: 75.
62. Flannery T. The Future Eaters. Sydney: Reed New Holland, 1994.
63. Berche P. The threat of smallpox and bioterrorism. Trends Microbiol. 2001; 9: 15-8.
64. O'Toole T. Smallpox: an attack scenario. Emerg. Infect. Dis. 1999; 5: 540-6.
65. Bardi J. Aftermath of a hypothetical smallpox disaster. Emerg. Infect. Dis. 1999; 5: 547-51.
66. Fauci AS. Editorial: Smallpox vaccination policy-the need for dialogue. NEJM 2002; 346: 1-2.
67. Australian Department of Health and Aged Care. Statement by Australia's Acting Chief Medical Officer: Smallpox Is a Low Threat in Australia. [Cited 7 Nov 2001.] Available at URL: www. health.gov.au/pubhlth/strateg/communic/factsheets/smallpox_statement.html
68. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull. World Health Organ. 1970; 4: 669-79.
69. Breman JG. Henderson DA. Diagnosis and management of smallpox. NEJM. 2002; 346: 1300-8.
70. Drazen JM. Smallpox and bioterrorism. NEJM 2002; 346: 1262-3.
71. Frey SE, Couch RB, Tacket CO et al. Clinical responses to undiluted and diluted smallpox vaccine. NEJM 2002; 346: 1265-74.
72. Fraser CM, Dando MR. Genomics and future biological weapons: the need for preventive action by the biomedical community. Nature Genet. 2001; 29: 253-6.
73. Dennis C. The bugs of war. Nature 2001; 411: 232-5.
74. Parkhill J, Wren BW, Thonson NR et al. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 2001; 413: 523-7.
75. Finkel E. Engineered mouse virus spurs bioweapon fears. Science 2001; 291: 585.
76. Jackson RJ, Ramsay AJ, Christensen CD et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 2001; 75: 1205-10.